API | lecozotan

lecozotan Report issue

Small molecule Experimental

AACT ChEMBL DrugBank PubChem

Active Ingredient History

NOW

Lecozotan is an investigational drug by Wyeth tested for improvement of cognitive functions of Alzheimer's disease patients. As of June 2008, the first Phase III clinical trial has been completed. ^Wikipedia

Chemistry

SMILES: C[C@H](CN(C(=O)c1ccc(cc1)C#N)c2ccccn2)N3CCN(CC3)c4cccc5OCCOc45
InChIKey: NRPQELCNMADTOZ-OAQYLSRUSA-N
Mol. Mass: 483.57
ALogP: 3.58 Partition coefficient
ChEMBL Molecules:

lecozotan

lecozotan hydrochloride

More Chemistry

Pharmacology

Mechanism of Action:
- 5-hydroxytryptamine receptor 1A (Homo sapiens) ^UniProt
Multi-specific: Missing data
Black Box: No
Availability: Missing data
Delivery Methods: Missing data
Pro Drug: No

lecozotan | lecozotan hcl | lecozotan hydrochloride | sra-333

Organizations (2)

Research & Development (2)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Marketing (0)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Indications (2)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (2)

Alzheimer Disease (Phase 2/Phase 3)

Healthy Volunteers (Phase 1)

Overview

Highest Phase: Phase 3
# of Trials: 8
# of Trial Organizations: 2

Trials by Phase

Trial	Phase	Start Date	Organizations	Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue